Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Balaxi PharmaceuticalsNSE:BALAXI -0.54%63 Quick Ratio is 2.70 as of Mar. 2026, which is 7% above its 10-year median of 2.53. GuruFocus rates NSE:BALAXI with a GF Score™ of 63/100 and a GF Value™ of ₹69.51 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 999 Drug Manufacturers companies, Balaxi Pharmaceuticals ranks better than 72.97% on this metric.
Balaxi Pharmaceuticals has a quick ratio of 2.70. It generally indicates good short-term financial strength.
The historical rank and industry rank for Balaxi Pharmaceuticals's Quick Ratio or its related term are showing as below:
NSE:BALAXI'
s Quick Ratio Range Over the Past 10 Years
Min: 0.67 Med: 2.53 Max: 51.23
Current: 2.7
During the past 12 years, Balaxi Pharmaceuticals's highest Quick Ratio was 51.23. The lowest was 0.67. And the median was 2.53.
NSE:BALAXI's Quick Ratio is ranked better than 72.97% of 999
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs NSE:BALAXI: 2.70
Balaxi Pharmaceuticals (NSE:BALAXI) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Balaxi Pharmaceuticals Quick Ratio Related Terms
Balaxi Pharmaceuticals Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Balaxi Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Balaxi Pharmaceuticals Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Balaxi Pharmaceuticals's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Balaxi Pharmaceuticals's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Balaxi Pharmaceuticals's Quick Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Balaxi Pharmaceuticals (NSE:BALAXI) has a Quick Ratio of 2.70 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Balaxi Pharmaceuticals and its competitors. This is near median its historical median of 2.53. Over the past decade, Balaxi Pharmaceuticals' Quick Ratio has ranged from 0.67 to 51.23. According to the industry distribution chart, Balaxi Pharmaceuticals ranks #270 out of 999 companies in the Drug Manufacturers industry, placing it in the top 27%.
Is Balaxi Pharmaceuticals' Quick Ratio too high?
Balaxi Pharmaceuticals' current Quick Ratio of 2.70 is near median its 10-year median of 2.53. Over the past 10 years, this metric has ranged from a low of 0.67 to a high of 51.23. The Drug Manufacturers industry median Quick Ratio is 1.45. Balaxi Pharmaceuticals' value of 2.70 is 86.2% above this industry median. Based on the distribution chart, Balaxi Pharmaceuticals ranks #270 out of 999 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Balaxi Pharmaceuticals has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Balaxi Pharmaceuticals' Quick Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Balaxi Pharmaceuticals ranks #270 out of 999 companies for Quick Ratio. This puts Balaxi Pharmaceuticals in the upper half of its industry. The industry median Quick Ratio is 1.45. Balaxi Pharmaceuticals' value of 2.70 is 86.2% above this benchmark. Historically, Balaxi Pharmaceuticals' own Quick Ratio has ranged from 0.67 to 51.23 over the past decade. While the company's 10-year median is 2.53 vs. the industry median of 1.45, Balaxi Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 999 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Balaxi Pharmaceuticals's current Quick Ratio of 2.70 is 86.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Balaxi Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Balaxi Pharmaceuticals's current Quick Ratio is 2.70, which is near median its own 10-year median of 2.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Balaxi Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Balaxi Pharmaceuticals (NSE:BALAXI) is currently considered Possible Value Trap. The stock's GF Value™ is ₹69.51, compared to a current price of ₹24.04 — trading 65.4% below its estimated fair value. The current Quick Ratio is 2.70, which is near median its 10-year median of 2.53 and 86.2% above the Drug Manufacturers industry median of 1.45. Balaxi Pharmaceuticals' overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Balaxi Pharmaceuticals (NSE:BALAXI), the current Quick Ratio is 2.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Balaxi Pharmaceuticals (NSE:BALAXI) Overvalued in 2026?
Based on GuruFocus' analysis, Balaxi Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹24.04 is trading 65.4% below its estimated GF Value™ of ₹69.51.
GuruFocus considers Balaxi Pharmaceuticals to be Possible Value Trap.
Key valuation signals for NSE:BALAXI:
Quick Ratio: 2.70 (near median its 10-year median of 2.53)
GF Value™: ₹69.51 vs. price of ₹24.04 (65.4% below fair value)
Industry Position: 86.2% above the Drug Manufacturers median (#270 of 999)
No single metric tells the full story. See the NSE:BALAXI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Balaxi Pharmaceuticals Ltd is an Indian branded IPR-based pharmaceutical company focusing on frontier markets, with a vast and growing portfolio of prescription and OTC drugs, across multiple therapeutic segments. The company operates in single segment Specialized Wholesale. Geographically it earns key revenue from Guatemala.
63GF Score
Get the complete analysis for NSE:BALAXI
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BALAXI has been successfully added to your 
